Market Research Report
Histone Deacetylase 6 - Pipeline Review, H2 2019
|Published by||Global Markets Direct||Product code||363572|
|Published||Content info||141 Pages
Delivery time: 1-2 business days
|Histone Deacetylase 6 - Pipeline Review, H2 2019|
|Published: December 27, 2019||Content info: 141 Pages||
Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 18.104.22.168) pipeline Target constitutes close to 49 molecules. Out of which approximately 40 molecules are developed by companies and remaining by the universities/institutes. The latest report Histone Deacetylase 6 - Pipeline Review, H2 2019, outlays comprehensive information on the Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 22.214.171.124) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 126.96.36.199) - Histone deacetylase 6 is an enzyme encoded by the HDAC6 gene. Histone deacetylation gives a tag for epigenetic repression and plays an important role in transcriptional regulation, cell cycle progression and developmental events. Histone deacetylases plays a central role in microtubule-dependent cell motility via deacetylation of tubulin. It is involved in the MTA1-mediated epigenetic regulation of ESR1 expression in breast cancer. It plays a key role in the degradation of misfolded proteins. It acts as an adapter that recognizes polyubiquitinated misfolded proteins and target them to the aggresome, facilitating their clearance by autophagy. The molecules developed by companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 5, 4, 1, 22 and 8 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 7 and 2 molecules, respectively. Report covers products from therapy areas Oncology, Central Nervous System, Genetic Disorders, Immunology, Toxicology, Gastrointestinal, Infectious Disease, Musculoskeletal Disorders and Undisclosed which include indications Multiple Myeloma (Kahler Disease), Alzheimer's Disease, Melanoma, Solid Tumor, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Charcot-Marie-Tooth Disease, Charcot-Marie-Tooth Disease Type II, Glioblastoma Multiforme (GBM), Multiple Sclerosis, Non-Small Cell Lung Cancer, Pancreatic Cancer, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Triple-Negative Breast Cancer (TNBC), Chemotherapy Induced Peripheral Neuropathy, Chronic Lymphocytic Leukemia (CLL), Colorectal Cancer, Depression, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Leukemia, Mantle Cell Lymphoma, Ovarian Cancer, Rheumatoid Arthritis, Squamous Cell Carcinoma, Systemic Lupus Erythematosus, Amyotrophic Lateral Sclerosis, Autoimmune Disorders, B-Cell Non-Hodgkin Lymphoma, Basal Cell Carcinoma (Basal Cell Epithelioma), Bile Duct Cancer (Cholangiocarcinoma), Blood Cancer, Breast Cancer, Burkitt Lymphoma, Cervical Cancer, CNS Lymphoma, Colon Cancer, Crohn's Disease (Regional Enteritis), Cutaneous T-Cell Lymphoma, Diabetic Neuropathic Pain, Endometrial Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Fibrosis, Gallbladder Cancer, Gastric Cancer, Gliosarcoma, High-Grade Glioma, Human Papillomavirus (HPV) Associated Cancer, Huntington Disease, Lung Adenocarcinoma, Lupus Nephritis, Lymphoma, Marginal Zone B-cell Lymphoma, Metastatic Biliary Tract Cancer, Metastatic Breast Cancer, Mycosis Fungoides, Myelodysplastic Syndrome, Neuroblastoma, Neurology, Neuropathic Pain (Neuralgia), Non-Hodgkin Lymphoma, NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma), Parkinson's Disease, Pediatric Diffuse Intrinsic Pontine Glioma, Peritoneal Cancer, Polycystic Kidney Disease, Rectal Cancer, Recurrent Medulloblastoma, Rett Syndrome, Sepsis, Tauopathies, Ulcerative Colitis and Unspecified.
Furthermore, this report also reviews key players involved in Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 188.8.131.52) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.